Bispecific antibodies against CD3EPSILON and ROR1
The present invention relates to bispecific antibodies against ROR1 and CD3, their manufacture and use.
1. A bispecific antibody which specifically binds human CD3ε comprising SEQ ID NO: 63 and an extracellular domain of human ROR1 comprising SEQ ID NO: 1, said bispecific antibody comprising:
(a) heavy chain polypeptides of SEQ ID NO: 37 and SEQ ID NO: 38, and light chain polypeptides of SEQ ID NO: 39 and SEQ ID NO: 40; or
(b) heavy chain polypeptides of SEQ ID NO: 37 and SEQ ID NO: 38, and light chain polypeptides of SEQ ID NO: 39 and SEQ ID NO: 41.
2. A method for preparing a bispecific antibody according to claim 1 comprising the steps of:
a) transforming a host cell with vectors comprising nucleic acid molecules encoding the bispecific antibody of claim 1 ,
b) culturing the host cell under conditions that allow synthesis of said bispecific antibody; and
c) recovering said bispecific antibody from said culture.
3. A host cell comprising vectors comprising nucleic acid molecules encoding the bispecific antibody of claim 1 .
4. A pharmaceutical composition comprising the bispecific antibody of claim 1 and a pharmaceutically acceptable excipient.
5. A nucleic acid molecule or nucleic acid molecules encoding the bispecific antibody of claim 1 .
6. A vector or vectors comprising the nucleic acid molecule or nucleic acid molecules of claim 5 .